Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, Patient Opportunity Equity Strategy returned 5.99% net of fees, compared to its unmanaged benchmark, the S&P 500 Index, which returned 2.65%. Through a three-factor performance attribution model, the portfolio’s outperformance was attributed to allocation, selection, and interaction effects. The market ended a strong year with 17.9% returns, marking the seventh-best three-year period in market history. 2025 was a year of AI, extending the benefits to hardware, energy, and component suppliers across the ecosystem. Seven stocks accounted for over half of the S&P 500’s returns, posing difficulties for active managers. Nevertheless, the strategy performed well, outperforming the S&P 500 for the third consecutive year with a return of 26.1%. Please review the Strategy’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Patient Opportunity Equity Strategy highlighted Precigen, Inc. (NASDAQ:PGEN) as one of its leading contributors. Precigen, Inc. (NASDAQ:PGEN) is a discovery and clinical-stage biopharmaceutical company focusing on developing gene and cell therapies in areas of immuno-oncology, autoimmune disorders, and infectious diseases. On March 04, 2026, Precigen, Inc. (NASDAQ:PGEN) stock closed at $3.55 per share. One-month return of Precigen, Inc. (NASDAQ:PGEN) was -16.27%, and its shares gained 89.84% over the past 52 weeks. Precigen, Inc. (NASDAQ:PGEN) has a market capitalization of $1.256 billion.
Patient Opportunity Equity Strategy stated the following regarding Precigen, Inc. (NASDAQ:PGEN) in its fourth quarter 2025 investor letter:
“Precigen, Inc. (NASDAQ:PGEN) continued to be a top contributor to the strategy following the early approval of Papziemos for the treatment of recurrent respiratory papillomatosis (RRP) in early August. With this approval, Papziemos became the first-in class “off-the-shelf” immunotherapy for a patient population with no other treatment options. As the company moves quickly to launch the drug, it inches closer to self-funding allowing it to advance its other pipeline assets toward approval. The company is led by Dr. Helen Sabzevari, who brings extensive expertise in immunotherapy-based therapeutics, having founded and served as Chief Scientific Officer of Compass Therapeutics. She has driven remarkable clinical progress at Precigen over the past few years, and we expect her to apply a similar playbook to their other pipeline assets in Phase 2 and Phase 1/1b development. We still see attractive upside given multiple blockbuster assets in development.”
Precigen, Inc. (NASDAQ:PGEN) is not on our list of 40 Most Popular Stocks Among Hedge Funds. According to our database, 19 hedge fund portfolios held Precigen, Inc. (NASDAQ:PGEN) at the end of the fourth quarter, compared to 26 in the previous quarter. While we acknowledge the risk and potential of Precigen, Inc. (NASDAQ:PGEN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Precigen, Inc. (NASDAQ:PGEN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Precigen, Inc. (NASDAQ:PGEN) and shared Goldman Sachs penny stocks. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
